Sertoli cell transplants: Their use in the treatment of neurodegenerative disease

Molecular Medicine Today

Volumn 4, Issue 11, 1998, Pages 471-477

  Willing, Alison E ^a   Cameron, Don F ^a   Sanberg, Paul R ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR;

CELL TRANSPLANTATION; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; IMMUNITY; NONHUMAN; PARKINSON DISEASE; REVIEW; SERTOLI CELL; XENOTRANSPLANTATION;

ANIMALS; CELL TRANSPLANTATION; FETAL TISSUE TRANSPLANTATION; GRAFT SURVIVAL; HUMANS; MALE; NEURODEGENERATIVE DISEASES; NEURONS; RATS; SERTOLI CELLS;

EID: 0031760391     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(98)01355-0     Document Type: Review

References (45)

1. Selawry H., Fojaco R., Whittington K. Intratesticular islet allografts in the spontaneously diabetic BB/W rat. Diabetes. 34:1985;1019-1023.
2. Cameron D.F.et al. Successful islet/abdominal testis transplantation does not require leydig cells. Transplantation. 50:1990;649-653.
3. Selawry H., Cameron D.F. Sertoli cell-enriched fractions in successful islet cell transplantation. Cell. Transplant. 2:1993;123-129.
4. Björklund A. Better cells for brain repair. Nature. 362:1993;414-415.
5. Dym M., Fawcett D.W. The blood-testis barrier in the rat and the physiological compartmentation of the seminiferous epithelium. Biol. Reprod. 3:1970;308-326.
6. Johnson M.H. The distribution of immunoglobulin and spermatozoal autoantigen in the genital tract of the male guinea pig. Fertil. Steril. 23:1972;383-392.
7. Pollanen P., Niemi M. Immunohistochemical identification of macrophages, lymphoid cells and HLA antigens in the human testis. Int. J. Androl. 10:1987;37-42.
8. Pollanen P., Maddocks S. Macrophages, lymphocytes and MHC II antigen in the ram and the rat testis. J. Reprod. Fertil. 32:1988;437-445.
9. Sanberg P.R.et al. Testis-derived Sertoli cells survive and provide localized immunoprotection for xenografts in rat brain. Nat. Biotechnol. 14:1996;1692-1695.
10. Wyatt C.R.et al. Suppression of lymphocyte proliferation by proteins secreted by cultured Sertoli cells. J. Reprod. Immunol. 14:1988;27-40.
11. Selawry H.et al. Production of a factor, or factors, suppressing IL-2 production and T-cell proliferation by Sertoli cell-enriched preparations. Transplantation. 52:1991;846-850.
12. Cantrell D.A., Smith K.A. The interleukin-2 T-cell system: a new cell growth model. Science. 224:1984;1312-1316.
13. Riccioli A.et al. Inflammatory mediators increase surface expression of integrin ligands, adhesion to lymphocytes, and secretion of interleukin 6 in mouse Sertoli cells. Proc. Natl. Acad. Sci. U. S. A. 92:1995;5808-5812.
14. Nagata S., Golstein P. The Fas death factor. Science. 267:1995;1449-1456.
15. Lau H.T.et al. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science. 273:1996;109-112.
16. Kang S.M.et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat. Med. 3:1997;738-743.
17. Bellgrau D.et al. A role for CD95 ligand in preventing graft rejection. Nature. 377:1995;630-632.
18. Takeda Y.et al. Protection of islet allografts transplanted together with Fas ligand expressing testicular allografts. Diabetologia. 41:1998;315-321.
19. Sanberg P.R.et al. The testis-derived cultured Sertoli cell as a natural Fas-L secreting cell for immunosuppressive cellular therapy. Cell Transplant. 6:1997;191-193.
20. Sanberg P.R.et al. Testis-derived Sertoli cells have a trophic effect on dopamine neurons and alleviate hemiparkinsonism in rats. Nat. Med. 3:1997;1129-1132.
21. Shaw L.M., Kaplan B., Kaufman D. Toxic effect of immunosuppressive drugs: mechanisms and strategies for controlling them. Clin. Chem. 42:1996;1316-1321.
22. Lindvall O. Neural transplantation: a hope for patients with Parkinson's disease. NeuroReport. 8:1997;3-10.
23. Kordower J.H.et al. Fetal grafting for Parkinson's disease: expression of immune markers in two patients with functional fetal nigral implants. Cell Transplant. 6:1997;213-219.
24. Skinner, M.D. (1993) Secretion of growth factors and other regulatory factors, in The Sertoli Cell (Russell, L.D. and Griswold, M.D., eds) pp. 237-248, Cache River Press.
25. Loveland K.L.et al. Platelet-derived growth factor ligand and receptor subunit mRNA in the Sertoli and Leydig cells of the rat testis. Mol. Cell. Endocrinol. 108:1995;155-159.
26. Widenfalk J.et al. Neurturin and glial cell line-derived neurotrophic factor receptor-β (GDNFR-β), novel proteins related to GDNF and GDNFR-α with specific cellular patterns of expression suggesting roles in the developing and adult nervous system and in peripheral organs. J. Neurosci. 17:1997;8506-8519.
27. Ling Z.D.et al. Differentiation of mesencephalic progenitor cells into dopaminergic neurons by cytokines. Exp. Neurol. 149:1998;411-423.
28. von Coelln R., Unsicker K., Krieglstein K. Screening of interleukins for survival-promoting effects on cultured mesencephalic dopaminergic neurons from embryonic rat brain. Dev. Brain. Res. 89:1995;150-154.
29. Morales C.R.et al. Expression and tissue distribution of rat sulfated glycoprotein-1 (prosaposin). J. Histochem. Cytochem. 44:1996;327-337.
30. Griswold M.D. Protein secretions of Sertoli cells. Int. Rev. Cytol. 110:1988;133-156.
31. Bitgood M.J., She L., McMahon A.P. Sertoli cell signaling by Desert hedgehog regulates the male germline. Curr. Biol. 6:1996;298-304.
32. Wang M.Z.et al. Induction of dopaminergic neuron phenotype in the midbrain by Sonic hedgehog protein. Nat. Med. 1:1995;1184-1188.
33. Zawada W.M.et al. Growth factors improve immediate survival of embryonic dopamine neurons after transplantation into rats. Brain Res. 786:1998;96-103.
34. Emerich D.W.et al. Cellular delivery of human CNTF prevents motor and cognitive dysfunction in a rodent model of Huntington's Disease. Cell. Transplant. 6:1997;249-266.
35. Gross C.E.et al. Transforming growth factor-beta 1 reduces infarct size after experimental cerebral ischemia in a rabbit model. Stroke. 24:1993;558-562.
36. Cameron D.F.et al. Post-thaw viability and functionality of cryopreserved rat fetal brain cells cocultured with Sertoli cells. Cell. Transplant. 6:1997;185-189.
37. Othberg A.I.et al. Porcine Sertoli cells enhance survival of dopaminergic rat embryonic ventral mesencephalic and human teratocarcinoma-derived neurons in vitro. Cell. Transplant. 7:1998;157-164.
38. Saporta S.et al. Survival of rat and porcine Sertoli cell transplants in the rat striatum without cyclosporine-A immunosuppression. Exp. Neurol. 146:1997;299-304.
39. Borlongan C.V.et al. Intracerebral transplantation of testis-derived Sertoli cells in female rats with 6-hydroxydopamine-induced hemiparkinsonism promotes functional recovery. Exp. Neurol. 148:1997;388-392.
40. Lapchak P.A.et al. Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease. Brain Res. 777:1997;153-160.
41. Westlund K.N.et al. NGF-producing transfected 3T3 cells: behavioral and histological assessment of transplants in nigral lesioned rats. J. Neurosci. Res. 41:1995;367-374.
42. Yoshimoto Y.et al. Astrocytes retrovirally transduced with BDNF elicit behavioral improvement in a rat model of Parkinson's disease. Brain Res. 691:1995;25-36.
43. US Food and Drug Administration (1996) Guidance concerning demonstration of comparability of human biological products, including therapeutic biotechnology-derived products, US Government Printing Office.
44. Mattson M.P.et al. Basic FGF regulates the expression of a functional 71 kDa NMDA receptor protein that mediates calcium influx and neurotoxicity in hippochampal neurons. J. Neurosci. 13:1993;4575-4588.
45. Koketsu M.et al. Pretreatment with intraventricular basic fibroblast growth factor decreases infarct size following focal cerebral ischemia in rats. Ann. Neurol. 35:1994;451-457.